An observational study in Vaginal Bleeding, sponsored by Rutgers, The State University of New Jersey. Completed at 3 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by Rutgers, The State University of New Jersey · Observational
Women presenting for contraception will be offered the IUS Skyla and study participation. Daily bleeding will be collected for a total of 90 days and correlated with insertion timing and baseline endometrial thickness.
156 studies on the registry are indexed under Uterine Hemorrhage; 19 are open to participants now.
This study's enrollment of 132 is close to the median of 121 across 40 observational studies indexed under Uterine Hemorrhage.
Browse Uterine Hemorrhage studies →Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women presenting for intrauterine device insertion.
Exclusion Criteria:
Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
Device: Intrauterine system
Participants in this group have the intrauterine system inserted during the remainder of their cycle.
Device: Intrauterine system
Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
Also known as: Intrauterine device
Bleeding and spotting as collected by daily texts
Composite variable of bleeding and spotting for 90 days after Skyla IUS insertion
Time frame: 90 days
Plan to share: No
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey